MLPA® Kits

For a description how to create and adapt MLPA Kits, that are not available on this page, please have a look at our User Manual MLPA.

Import of SALSA MLPA® kit descriptions via the SEQUENCE Pilot operation "Mixes [master file] / button [Import]".

Mix
Version
Date
Region
Application
Vs. 05
19-01-2010
Various Chronic Lymphocytic Leukemia (CLL)
Vs. 09
21-12-2012
Various Chronic Lymphocytic Leukemia (CLL)
Vs. 10
12-08-2015
Various Chronic Lymphocytic Leukemia (CLL)
Vs. 11
11-12-2015
Various Chronic Lymphocytic Leukemia (CLL)
Vs. 10
21-12-2012
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 11
23-06-2013
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 12
03-11-2014
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. B1/B2-01
28-03-2017
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 08
03-01-2011
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 09
13-03-2012
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 11
23-06-2013
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. 12
03-11-2014
ATM 11q23 Ataxia-Telangiectasia (AT)
Vs. B1/B2-01
28-03-2017
ATM 11q23 Ataxia-Telangiectasia (AT)
P043-C1 Vs. 25 25-07-2012 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-C1 Vs. 26 26-11-2012 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-C1 Vs. 27 15-02-2013 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-D1 Vs. 28 28-11-2013 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-E1 Vs. 29 03-03-2017 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-E1 Vs. 30 19-06-2017 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
P043-E1 Vs. E1-01 25-07-2017 APC, 5q21-q22 Hereditary Polyposis Colon Cancer
Vs. 07
29-05-2008
NF2 22q12 Neurofibromatosis type 2 (NF2)
Vs. 08
08-07-2010
NF2 22q12 Neurofibromatosis type 2 (NF2)
Vs. 12
26-12-2012
NF2 22q12 Neurofibromatosis type 2 (NF2)
Vs. 13
01-03-2013
NF2 22q12 Neurofibromatosis type 2 (NF2)
Vs. 14
14-05-2013
NF2 22q12 Neurofibromatosis type 2 (NF2)
P044-B2
Vs. 15
12-08-2015
NF2 22q12 Neurofibromatosis type 2 (NF2)
P044-B3
Vs. 16
24-11-2016
NF2 22q12 Neurofibromatosis type 2 (NF2)
Vs. 28
14-03-2014
BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
Vs. 29
05-11-2014
BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-B3 Vs. 31 18-02-2015 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-B3 Vs. 32 27-05-2015 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-B3 Vs. 33 09-09-2015 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-C1 Vs. 34 21-07-2016 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-C1 Vs. C1-01 05-12-2016 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-C1 Vs. C1-02 08-06-2017 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
P045-C1 Vs. C1-03 26-09-2017 BRCA2 13q12.3, CHEK2 22q12.1 Breast cancer, hereditary
Vs. 07
15-03-2012
TSC2 16p13.3 Tuberous Sclerosis
Vs. 09
01-03-2013
TSC2 16p13.3 Tuberous Sclerosis
P046-C1 Vs. 11 26-03-2015 TSC2 16p13.3 Tuberous Sclerosis
P046-C1 Vs. 12 26-11-2015 TSC2 16p13.3 Tuberous Sclerosis
P046-C1 Vs. 13 10-02-2017 TSC2 16p13.3 Tuberous Sclerosis
Vs. 13
12-06-2010
RB1 13q14 Retinoblastoma (RB)
P047-C1 Vs. 16 27-03-2012 RB1 13q14 Retinoblastoma (RB)
P047-C1 Vs. 17 25-11-2012 RB1 13q14 Retinoblastoma (RB)
P047-D1 Vs. 18 17-10-2014 RB1 13q14 Retinoblastoma (RB)
P047-D1 Vs. 19 02-12-2016 RB1 13q14 Retinoblastoma (RB)
P047-E1 Vs. 20 13-12-2017 RB1 13q14 Retinoblastoma (RB)
Vs. 12
07-09-2011
LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
Vs. 14
27-04-2012
LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
Vs. 15
21-12-2012
LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
P048-C1 Vs. 16 12-08-2015 LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
P048-C1 Vs. 17 01-07-2016 LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
P048-C2 Vs. 18 21-02-2017 LMNA 1q21.2-1q21.3 Laminopathies, Limb-girdle muscular dystrophy, Myofibrillar myopathies
Vs. 06
24-09-2011
SLC6A8, Xq28 Creatine transporter, x-linked
Vs. 08
06-06-2012
SLC6A8, Xq28 Creatine transporter, x-linked
Vs. 09
25-11-2012
SLC6A8, Xq28 Creatine transporter, x-linked
Vs. 10
13-05-2014
SLC6A8, Xq28 Creatine transporter, x-linked
Vs. 11
07-12-2015
SLC6A8, Xq28 Creatine transporter, x-linked
Vs. 27
13-03-2012
CYP21A2 6p21.3 Congenital adrenal hyperplasia
Vs. 28 21-12-2012 CYP21A2 6p21.3 Congenital adrenal hyperplasia
P050-C1 Vs. 29 02-08-2013 CYP21A2 6p21.3 Congenital adrenal hyperplasia
P050-C1 Vs. 30 29-10-2013 CYP21A2 6p21.3 Congenital adrenal hyperplasia
P050-C1 Vs. 31 07-10-2014 CYP21A2 6p21.3 Congenital adrenal hyperplasia
P050-C1 Vs. 33 20-02-2017 CYP21A2 6p21.3 Congenital adrenal hyperplasia
P050-C1 Vs. 35 16-08-2017 CYP21A2 6p21.3 Congenital adrenal hyperplasia
Vs. 18
29-10-2009
PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 20
03-01-2012
PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 21
21-12-2012 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 22
04-06-2013 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 24
19-12-2013 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 26
25-07-2014 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 27
16-01-2015 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 18
29-10-2009
PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 20
06-01-2012
PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 21 21-12-2012 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 22 04-06-2013 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 24 19-12-2013 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 26 25-07-2014 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
Vs. 27
16-01-2015 PARK2 6q25.2, SNCA 4q21, Pink1, Park7 1p36 Parkinson disease, familial
P054-B1 Vs. 10 22-02-2012 FOXL2, TWIST1, FOXC1, FOXC2, ATR, PITX2, GPR143 Ophthalmogenetic anomalies
P054-B1 Vs. 11 30-11-2012 FOXL2, TWIST1, FOXC1, FOXC2, ATR, PITX2, GPR143 Ophthalmogenetic anomalies
P054-B2 Vs.12 31-01-2014 FOXL2, TWIST1, FOXC1, FOXC2, ATR, PITX2, GPR143 Ophthalmogenetic anomalies
P054-C1 Vs.14 07-11-2014 FOXL2, TWIST1, FOXC1, FOXC2, ATR, PITX2, GPR143 Ophthalmogenetic anomalies
P054-C2 Vs.16 09-08-2017 FOXL2, TWIST1, FOXC1, FOXC2, ATR, PITX2, GPR143 Ophthalmogenetic anomalies
Vs. 04
14-04-2011
PAH 12q24.1 Phenylketonuria
Vs. 05
01-02-2012
PAH 12q24.1 Phenylketonuria
Vs. 07
21-12-2012
PAH 12q24.1 Phenylketonuria
Vs. 09
03-03-2015
PAH 12q24.1 Phenylketonuria
Vs. D1-01
18-01-2016
PAH 12q24.1 Phenylketonuria
Vs. 09
08-02-2012
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 10
04-07-2012
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 11
21-12-2012
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 12
16-05-2013
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 13
21-03-2014
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 14
14-09-2014
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 15
02-02-2015
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 16
23-04-2015
P53 17q13.1 Li-Fraumeni syndrome (LFS)
Vs. 09
22-04-2008
FANCD2. 3p25.3, PALB2 16p12 Fanconi anemia (FA)
Vs. 17
21-12-2012
FANCD2. 3p25.3, PALB2 16p12 Fanconi anemia (FA)
Vs. 18
24-06-2015
FANCD2. 3p25.3, PALB2 16p12 Fanconi anemia (FA)
Vs. 04
01-03-2010
IGHMBP2 11q13 Distal spinal muscular atrophy 1 (DSMA1), SMARD1, dHMN6
P058-A2 Vs. 08 21-12-2012 IGHMBP2 11q13 Distal spinal muscular atrophy 1 (DSMA1), SMARD1, dHMN6
P058-A3 Vs. 10 17-11-2016 IGHMBP2 11q13 Distal spinal muscular atrophy 1 (DSMA1), SMARD1, dHMN6
Vs. 01
08-02-2012
  Dystonia
Vs. 03
04-04-2014
  Dystonia